Ibex Investors’s Amedisys AMED Stock Holding History

Ibex Investors’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-1,976	Closed	-$232K	–	59
2018 Q4	$232K	Buy	1,976 +254	+15%	+$29.9K	0.04%	67
2018 Q3	$215K	Buy	+1,722	New	+$190K	0.12%	76

Other funds holding AMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Ibex Investors's AMED Position: Q1 2019 in Review

Ibex Investors sold out of Amedisys (AMED) in Q1 2019, closing a stake of 1,976 shares — an estimated $232K sold.

Ibex Investors first reported a position in AMED in Q3 2018 and held it in 2 quarters. The position peaked at $232K in Q4 2018. 317 funds tracked by Wall St. Rank hold AMED as of Q1 2019.

Ibex Investors reported no remaining Amedisys position as of Q1 2019 after selling out during the quarter.
Ibex Investors sold 1,976 Amedisys shares in Q1 2019, an estimated $232K.
Ibex Investors first reported a position in Amedisys in Q3 2018 and held it in 2 quarters.
Ibex Investors's Amedisys position peaked at $232K in Q4 2018.
317 funds tracked by Wall St. Rank held Amedisys as of Q1 2019.

Based on Ibex Investors's 13F filing for Q1 2019, filed 7 May 2019.